AbCelex licenses NRC platform technology

Toronto's AbCelex Technologies Inc has signed an exclusive worldwide licensing agreement with the National Research Council's Institute for Biological Sciences to access its Pentabody platform technology. The privately-held firm will pay NRC an upfront payment, milestone payments and royalties based on future product sales for the technology, which will be used for all of its vitro clinical diagnostic applications. AbCelex develops products for the rapid diagnosis of a wide range of disease-associated biomolecules. www.abcelex.com….